SCMP News Alert Sucampo Pharmaceuticals (SCMP) 14.22 01/03/2015

New Post Public Reply Private Reply Replies (0) Message Board

Jan 3, 2015 at 3:14 PM

Sucampo Pharmaceuticals (SCMP) 14.22 $SCMP

RedHill's Bekinda Accepted for Review in the EU, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 02, 3:40PM CST
Shares of RedHill Biopharma Ltd. (RDHL) surged after the company announced that the UK Medicines and Healthcare Products Regulatory Agency has validated its Marketing Authorization Application for its pipeline candidate Bekinda.
RDHL: 13.79 (+0.46), SCMP: 14.22 (-0.06), GSK: 42.37 (-0.37), BIOD: 1.39 (+0.06)

ARIAD & Angelini Team Up to Commercialize Iclusig in Europe - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 31, 1:35PM CST
ARIAD Pharmaceuticals, Inc. (ARIA) announced that it has granted exclusive rights to privately-held pharmaceutical company Angelini Pharma to commercialize Iclusig in Central and Eastern Europe.
ARQL: 1.24 (+0.02), SCMP: 14.22 (-0.06), ARIA: 6.89 (+0.02), BIOD: 1.39 (+0.06)

Alexion Seeks FDA Approval for its Hypophosphatasia Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 31, 10:05AM CST
Alexion Pharmaceuticals is looking to get asfotase alfa approved in the U.S. for treating patients suffering from hypophosphatasia.
ACT: 259.13 (+1.72), SCMP: 14.22 (-0.06), ALXN: 186.60 (+1.57), AFFX: 9.99 (+0.12)

Daily Pharma Dose: New Research on Hospira, Aquinox, Sucampo, NephroGenex and OncoGenex
PR Newswire - Wed Dec 31, 8:10AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Hospira (NYSE: HSP), Aquinox (NASDAQ: AQXP), Sucampo (NASDAQ: SCMP), NephroGenex (NASDAQ: NRX), and OncoGenex (NASDAQ: OGXI). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
AQXP: 7.63 (+0.13), OGXI: 2.32 (+0.03), NRX: 10.68 (-2.67), SCMP: 14.22 (-0.06), HSP: 61.87 (+0.62)

Canada accepts Sucampo's NDS for constipation med
Seeking Alpha - at Seeking Alpha - Wed Dec 31, 6:38AM CST

SCMP: 14.22 (-0.06)

Sucampo Announces Acceptance of New Drug Submission for AMITIZA(R) (lubiprostone) by Health Canada
GlobeNewswire - Tue Dec 30, 4:00PM CST
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that Health Canada has accepted the company's New Drug Submission (NDS) for AMITIZA (lubiprostone), 24 mcg capsules, for the treatment of chronic idiopathic constipation in adults and opioid induced constipation in adults with chronic non-cancer pain.
SCMP: 14.22 (-0.06)

97.0% Return Seen to Date on SmarTrend Sucampo Pharmaceuticals Call (SCMP)
Comtex SmarTrend(R) - Fri Dec 26, 9:03AM CST
SmarTrend identified an Uptrend for Sucampo Pharmaceuticals (NASDAQ:SCMP) on August 13th, 2014 at $6.98. In approximately 5 months, Sucampo Pharmaceuticals has returned 96.99% as of today's recent price of $13.75.
SCMP: 14.22 (-0.06)

Keryx (KERX) Launches Renal Drug Auryxia in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 3:35PM CST
Keryx Biopharmaceuticals, Inc. (KERX) announced it has begun to ship Auryxia (ferric citrate) tablets to wholesalers in the U.S.
AGN: 212.75 (+0.16), SHPG: 209.01 (-3.53), SCMP: 14.22 (-0.06), KERX: 14.34 (+0.19)

Gilead/Ono Pharmaceutical Ink Deal for Blood Cancer Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 22, 3:12PM CST
Gilead Sciences, Inc. and Ono Pharmaceutical Co., Ltd. announced that they have entered into an agreement for ONO-4059.
VRX: 144.45 (+1.34), GILD: 94.91 (+0.65), SCMP: 14.22 (-0.06)

Emergent BioSolutions Buys EV-035 Series from Evolva - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 3:45PM CST
Emergent BioSolutions Inc. announced that it has entered into an agreement with Evolva Holding for acquiring the latter's anti-bacterial program.
ACT: 259.13 (+1.72), VRX: 144.45 (+1.34), EBS: 26.90 (-0.33), SCMP: 14.22 (-0.06)

UCB's Kremers Urban Sale Deal Lapses, Divestiture Plan On - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 18, 2:20PM CST
UCB (UCBJF), Advent International and Avista Capital Partners announced their decision to mutually terminate their deal for the acquisition of UCB's Kremers Urban.
LCI: 43.28 (+0.40), VRX: 144.45 (+1.34), SCMP: 14.22 (-0.06)

Uptrend Call Working As Sucampo Pharmaceuticals Stock Rises 92.8% (SCMP)
Comtex SmarTrend(R) - Thu Dec 18, 9:35AM CST
SmarTrend identified an Uptrend for Sucampo Pharmaceuticals (NASDAQ:SCMP) on August 13th, 2014 at $6.98. In approximately 4 months, Sucampo Pharmaceuticals has returned 92.84% as of today's recent price of $13.46.
SCMP: 14.22 (-0.06)

Cyclacel Falls on Poor Acute Myeloid Leukemia Drug Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 17, 4:00PM CST
In the SEAMLESS study on sapacitabine, the DSMB found that the planned futility boundary has been crossed.
ACT: 259.13 (+1.72), VRX: 144.45 (+1.34), CYCC: 0.70 (unch), SCMP: 14.22 (-0.06)

Salix Gains on Destocking Initiatives, Gives 2-Year Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 17, 1:12PM CST
Salix (SLXP) expects to resolve its inventory situation a year ahead of schedule and now expects a FDA response on Xifaxan 550 by May 27, 2015.
LCI: 43.28 (+0.40), SCMP: 14.22 (-0.06), SLXP: 114.74 (-0.20), BIOD: 1.39 (+0.06)

Alexion Announces New Share Repurchase Program of $500M - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 5:55PM CST
Alexion Pharmaceuticals, Inc. (ALXN) announced that a new share repurchase program of up to $500 million have been authorized by its board of directors.
ACT: 259.13 (+1.72), VRX: 144.45 (+1.34), SCMP: 14.22 (-0.06), ALXN: 186.60 (+1.57)

Sophiris Plunges on Disappointing Data on its BPH Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 3:30PM CST
Sophiris Bio Inc.'s (SPHS) shares plummeted 81.5% after the company announced disappointing data from an interim efficacy analysis of its ongoing phase III study on PRX302.
ACT: 259.13 (+1.72), VRX: 144.45 (+1.34), SPHS: 0.55 (+0.01), SCMP: 14.22 (-0.06)

Calithera Biosciences Slumps: CALA Tanks 10.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 7:50AM CST
Calithera Biosciences (CALA) fell by over 10% in the last trading session amid huge volumes, reversing its recent uptrend, as the stock is now up nearly 185% in the past one month.
LCI: 43.28 (+0.40), SCMP: 14.22 (-0.06), CALA: 20.90 (+0.70), IG: 9.07 (+0.27)

Sucampo names John H. Johnson to board
M2 - Tue Dec 16, 6:04AM CST
Biopharmaceutical company Sucampo Pharmaceuticals (NasdaqGM:SCMP)revealed on Monday the election of John H. Johnson to its board of directors.
PTLA: 28.51 (+0.19), SCMP: 14.22 (-0.06)

One Stock Chart Trick You Should All Know - Investment Ideas
David Bartosiak - ZACKS - Tue Dec 16, 12:00AM CST
One Stock Chart Trick You Should All Know - Investment Ideas
HSKA: 18.03 (-0.10), ANIP: 56.99 (+0.60), SCMP: 14.22 (-0.06)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AI-Driven Lumi Transforms Car Dealership Interactions

Lumi: Changing the Car Buying Game Picture this: You're browsing for a new car, head filled with specifics like towing capacity, price points, and trim options. Usually, such queries would send you bouncing around the web, but Lectrium's Lumi promises to keep the questioning—and decision-making—right on the dealership's page. In a move set to shake up the game,...

Compass Unveiled: Power Revolution in Private Equity

AI-Driven Insights: Revolutionizing Private Equity Strategies Now this is some spicy news from Huntington Beach! Collective just pulled back the curtain on Compass, their AI-fueled platform that's set to shake up how financial advisors tackle private company equity. If you're an advisor who's sick of staring at nebulous balance sheets filled with unquantifiable private...

HTX's Strategic Moves in Pakistan: A Crypto Frontier

Paving the Way: HTX's Journey in Pakistan Rolling into the Pakistan cryptocurrency scene isn't just a 'walk in the park' for HTX—it's more like traversing a new frontier with an open map. This isn’t some hit-and-run operation; HTX is strategizing for a long haul in one of the liveliest digital market arenas in South Asia. Gathering steam with community AMAs and an X...

Succession Planning in Turmoil: Only 42% Ready

Diving into the Succession Crisis in Finance Succession planning in the financial advisory space is like retirement planning for the rest of us—everyone knows it's crucial, yet too many put it off. Despite the looming retirement wave and desperate interest from the younger cohort, a staggering 42% of financial advisors are still without a documented succession game...

Sean Trahan Joins Citrin Cooperman: New Tax Lead

Citrin Cooperman's Strategic Tax Move If there's one phrase that can spark a debate at a financial water cooler, it's 'transfer pricing.' Today, Citrin Cooperman is throwing its hat further into that ring with the appointment of Sean Trahan as head of their new Transfer Pricing and Value Chain Optimization Practice. This isn't just another reshuffling of office...

K-Beauty Takes Front Stage at Target Beauty Studio

Making Waves in the U.S. with K-Beauty SUNGBOON EDITOR and Milk Touch just rolled into Target Beauty Studio, making a splash in the world of K-beauty. From ingredients that boast serious benefits to playful cosmetics that let you express yourself, these brands are shaking up American beauty routines in a big way. Ingredient-Focused Skincare for Every American Face...

Machine Grabs Prime Dallas Property Amid Apartment Boom

Dallas' Hot Market and Machine's Bold Move Well, well, looks like Machine Investment Group's been busy flexing its real estate muscles, bagging a 490-unit gem in North Dallas—your typical, no-frills off-market grab. We’re talking 75 West, nestled in a juicy infill spot, and it’s catching eyes like gold dust in a pan. You don't need me to tell you North Dallas ain't...

Davos Healthcare Aims to Revolutionize Hospital Ratings

Throw away those dusty, old reputation surveys—Davos Healthcare just turned the spotlight onto cold, hard data with its new global hospital evaluation platform. Why Davos Healthcare’s Initiative Matters At the C3 US NYC Davos of Healthcare™ Summit, an event that’s rooted itself alongside the United Nations General Assembly, Davos Healthcare unveiled a...

Dr. Desi Bartlett Teams Up with Glo for Perimenopause Focus

Glo Taps Top Wellness Expert for Women's Health Initiative In an industry brimming with wellness voices, it's rare to find one that marries scholarly acumen with authentic, personal teaching. Yet, this is precisely what Dr. Desi Bartlett brings to the table as she partners with Glo to offer new fitness programming specifically targeting women facing perimenopause and...

FJBio Boosts Antibody Discovery with Sapio AI

In the sprawling world of antibody discovery, where every scrap of data can make or break the next big breakthrough, FairJourney Bio (FJBio) is pulling out all the stops. They've teamed up with Sapio Sciences to ditch the paperwork nightmares and usher in a new era of AI-driven efficiency. With operations stretching from Porto to Cambridge to sunny San Diego, they’re...